Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|SMAD4 dec exp||colorectal cancer||not applicable||N/A||Clinical Study||Prognostic||In clinical and meta-analyses, decreased expression of Smad4 was correlated with poor prognosis in colorectal cancer (PMID: 25749173, PMID: 19478385, PMID: 25681512, PMID: 26861460).||25749173 19478385 26861460 25681512|
|PubMed Id||Reference Title||Details|
|(25749173)||A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer.||Full reference...|
|(26861460)||Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.||Full reference...|
|(25681512)||Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.||Full reference...|
|(19478385)||Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.||Full reference...|